Abivax S.A.(us:ABVX)
5.89
-5.76%
Updated on 2025-04-02
Open:6.26
Close:5.89
High:6.26
Low:5.76
Prev Close:6.25
Volume:216501.00
Turnover:1.30M
Turnover Ratio:0.34%
Shares:63.38M
MarketCap:373.33M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-03-31 | 41 | 23372028 | 37.15% | 12 | 9 | 11 |
| 2023-12-31 | 30 | 21265859 | 33.80% | 30 | 0 | 0 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Deep Track Capital, Lp | 4297438 | 6.83% | 0 | |
| 2024-03-31 | Great Point Partners I Lp | 2488483 | 3.96% | 938483 | 60.55% |
| 2024-03-31 | Cormorant Asset Management, Lp | 2130000 | 3.39% | 0 | |
| 2024-03-31 | Blackstone Inc. | 2117610 | 3.37% | -251112 | -10.60% |
| 2024-03-31 | Commodore Capital Lp | 1895003 | 3.01% | 0 | |
| 2024-03-31 | Franklin Resources Inc | 1395052 | 2.22% | 145757 | 11.67% |
| 2024-03-31 | Vr Adviser, Llc | 1345780 | 2.14% | 347210 | 34.77% |
| 2024-03-31 | Tcg Crossover Management, Llc | 1100000 | 1.75% | 0 | |
| 2024-03-31 | Nantahala Capital Management, Llc | 1010034 | 1.61% | 0 | |
| 2024-03-31 | Janus Henderson Group Plc | 851839 | 1.35% | 131414 | 18.24% |
About
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Address:7-11 Boulevard Haussmann
Website:http://www.abivax.com
Market Movers